A detailed history of First Manhattan CO transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, First Manhattan CO holds 1,570 shares of VRTX stock, worth $708,022. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,570
Previous 1,555 0.96%
Holding current value
$708,022
Previous $728,000 0.27%
% of portfolio
0.0%
Previous 0.0%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$460.0 - $505.78 $6,900 - $7,586
15 Added 0.96%
1,570 $730,000
Q2 2024

Aug 13, 2024

BUY
$392.81 - $485.53 $392 - $485
1 Added 0.06%
1,555 $728,000
Q1 2024

May 15, 2024

BUY
$407.69 - $446.08 $27,722 - $30,333
68 Added 4.58%
1,554 $649,000
Q4 2023

Feb 13, 2024

SELL
$343.0 - $410.68 $25,382 - $30,390
-74 Reduced 4.74%
1,486 $604,000
Q3 2023

Nov 14, 2023

BUY
$338.18 - $362.46 $2,367 - $2,537
7 Added 0.45%
1,560 $542,000
Q2 2023

Aug 14, 2023

BUY
$314.42 - $351.91 $8,803 - $9,853
28 Added 1.84%
1,553 $546,000
Q1 2023

May 15, 2023

SELL
$283.23 - $323.1 $9,629 - $10,985
-34 Reduced 2.18%
1,525 $480,000
Q4 2022

Feb 14, 2023

BUY
$285.76 - $321.48 $2,571 - $2,893
9 Added 0.58%
1,559 $450,000
Q3 2022

Nov 14, 2022

SELL
$273.83 - $305.53 $54,766 - $61,105
-200 Reduced 11.43%
1,550 $448,000
Q2 2021

Aug 16, 2021

SELL
$187.49 - $221.1 $74,996 - $88,440
-400 Reduced 18.6%
1,750 $352,000
Q1 2021

May 14, 2021

SELL
$207.02 - $241.31 $20,702 - $24,131
-100 Reduced 4.44%
2,150 $462,000
Q4 2020

Feb 16, 2021

SELL
$207.01 - $276.09 $6,417 - $8,558
-31 Reduced 1.36%
2,250 $531,000
Q3 2020

Nov 12, 2020

SELL
$255.65 - $303.1 $18,918 - $22,429
-74 Reduced 3.14%
2,281 $620,000
Q2 2020

Aug 14, 2020

BUY
$225.48 - $295.8 $5,637 - $7,395
25 Added 1.07%
2,355 $683,000
Q1 2020

May 06, 2020

BUY
$199.77 - $247.81 $35,958 - $44,605
180 Added 8.37%
2,330 $554,000
Q4 2019

Feb 13, 2020

BUY
$166.71 - $223.91 $41,677 - $55,977
250 Added 13.16%
2,150 $470,000
Q3 2019

Nov 13, 2019

BUY
$166.23 - $187.09 $166,230 - $187,090
1,000 Added 111.11%
1,900 $321,000
Q2 2019

Aug 16, 2019

SELL
$164.61 - $190.37 $4,115 - $4,759
-25 Reduced 2.7%
900 $165,000
Q1 2019

Apr 12, 2019

BUY
$163.73 - $194.7 $16,372 - $19,470
100 Added 12.12%
925 $170,000
Q2 2018

Aug 01, 2018

SELL
$145.72 - $169.96 $218,580 - $254,940
-1,500 Reduced 64.52%
825 $140,000
Q1 2018

Apr 20, 2018

SELL
$151.6 - $177.13 $21,224 - $24,798
-140 Reduced 5.68%
2,325 $378,000
Q4 2017

Jan 22, 2018

BUY
$137.28 - $155.55 $19,219 - $21,777
140 Added 6.02%
2,465 $369,000
Q3 2017

Oct 25, 2017

BUY
$148.13 - $162.24 $344,402 - $377,208
2,325
2,325 $353,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $116B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track First Manhattan CO Portfolio

Follow First Manhattan CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Manhattan CO, based on Form 13F filings with the SEC.

News

Stay updated on First Manhattan CO with notifications on news.